[go: up one dir, main page]

PE20181541A1 - Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco - Google Patents

Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco

Info

Publication number
PE20181541A1
PE20181541A1 PE2018001272A PE2018001272A PE20181541A1 PE 20181541 A1 PE20181541 A1 PE 20181541A1 PE 2018001272 A PE2018001272 A PE 2018001272A PE 2018001272 A PE2018001272 A PE 2018001272A PE 20181541 A1 PE20181541 A1 PE 20181541A1
Authority
PE
Peru
Prior art keywords
terminal
amino acids
derivatives
appls
compounds
Prior art date
Application number
PE2018001272A
Other languages
English (en)
Inventor
Yizhou Dong
Kevin Thomas Love
Robert S Langer
Daniel Griffith Anderson
Delai Chen
Yi Chen
Arturo Jose Vegas
Akinleye Alabi
Yunlong Zhang
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of PE20181541A1 publication Critical patent/PE20181541A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/60—1,4-Diazines; Hydrogenated 1,4-diazines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Se refiere a compuestos APPLs y composiciones que se caracterizan por las formulas Markush (I), (II), (III), (IV), (V) y (VI), en donde al menos un grupo amino terminal esta adicionalmente funcionalizado al tener un grupo del tipo (i), (ii) o (iii), dichos compuestos se obtienen haciendo reaccionar un grupo amino terminal o interno con epoxidos, acrilatos o aldehidos que tienen grupos lipofilicos; los aminoacidos, peptidos, polipeptido-lipidos resultantes (llamados "APPLs"). Los compuestos APPLs son utiles en terapia de genes como la capacidad de unirse a polinucleotidos, bioprocesamiento o la administracion y/o suministro de un agente terapeutico, entre otros.
PE2018001272A 2011-10-27 2012-10-26 Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco PE20181541A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161552423P 2011-10-27 2011-10-27

Publications (1)

Publication Number Publication Date
PE20181541A1 true PE20181541A1 (es) 2018-09-26

Family

ID=47146733

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2018001272A PE20181541A1 (es) 2011-10-27 2012-10-26 Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
PE2014000601A PE20150041A1 (es) 2011-10-27 2012-10-26 Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2014000601A PE20150041A1 (es) 2011-10-27 2012-10-26 Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco

Country Status (19)

Country Link
US (5) US9512073B2 (es)
EP (2) EP4074694A1 (es)
JP (5) JP6151707B2 (es)
KR (4) KR102596685B1 (es)
CN (3) CN113149869A (es)
AU (4) AU2012328570B2 (es)
BR (1) BR112014010050A2 (es)
CA (2) CA3119789A1 (es)
CL (1) CL2014001070A1 (es)
EA (2) EA032088B1 (es)
ES (1) ES2912739T3 (es)
IL (4) IL232158A (es)
MX (2) MX363734B (es)
NZ (1) NZ747501A (es)
PE (2) PE20181541A1 (es)
SG (1) SG11201401885TA (es)
UA (1) UA119028C2 (es)
WO (1) WO2013063468A1 (es)
ZA (1) ZA201802716B (es)

Families Citing this family (353)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05007322A (es) 2003-01-06 2006-02-17 Angiochem Inc Aprotinina y analogos como portadores a traves de la barrera sangre-cerebro.
WO2006138380A2 (en) * 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
BRPI0910557A2 (pt) 2008-04-18 2015-09-29 Angiochem Inc composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.
AU2009304560A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of GLP-1 agonists and uses thereof
WO2010043049A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
MX353900B (es) 2008-11-07 2018-02-01 Massachusetts Inst Technology Lipidoides de aminoalcohol y usos de los mismos.
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
WO2010069074A1 (en) 2008-12-17 2010-06-24 Universite Du Quebec A Montreal Membrane type-1 matrix metalloprotein inhibitors and uses thereof
ES2729261T3 (es) 2009-04-20 2019-10-31 Angiochem Inc Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2
MX2012000016A (es) 2009-07-02 2012-03-26 Angiochem Inc Conjugados de peptidos multimericos y sus usos.
LT2506857T (lt) 2009-12-01 2018-07-10 Translate Bio, Inc. Mrnr tiekimas baltymų ir fermentų papildymui žmogaus genetinių ligų atvejais
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
ES2862955T5 (en) 2010-10-01 2025-01-29 Modernatx Inc Engineered nucleic acids and methods of use thereof
CA2831392C (en) 2011-03-28 2020-04-28 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
ES2795110T3 (es) 2011-06-08 2020-11-20 Translate Bio Inc Lípidos escindibles
PL3586861T3 (pl) 2011-06-08 2022-05-23 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN110511939A (zh) 2011-10-03 2019-11-29 现代泰克斯公司 修饰的核苷、核苷酸和核酸及其用途
JP6151707B2 (ja) 2011-10-27 2017-06-21 マサチューセッツ インスティテュート オブ テクノロジー 薬物内包微小球の形成が可能なｎ−末端で官能基化されたアミノ酸誘導体
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US20140010861A1 (en) 2012-04-02 2014-01-09 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US20150267192A1 (en) 2012-06-08 2015-09-24 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
CA2884870C (en) 2012-08-13 2022-03-29 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
EP4446413A3 (en) 2013-03-14 2024-12-18 Translate Bio, Inc. Methods for purification of messenger rna
SMT202100430T1 (it) 2013-03-14 2021-09-14 Translate Bio Inc Metodi e composizioni per il rilascio di anticorpi codificati da mrna
ES2689523T3 (es) 2013-03-14 2018-11-14 Translate Bio, Inc. Composiciones a base de ARNM del gen CFTR y métodos y usos relacionados
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2971165A4 (en) 2013-03-15 2016-11-23 Moderna Therapeutics Inc DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
JP2016530294A (ja) 2013-09-03 2016-09-29 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． キメラポリヌクレオチド
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
CN106413811A (zh) * 2013-10-22 2017-02-15 夏尔人类遗传性治疗公司 精氨基琥珀酸合成酶缺乏症的mrna疗法
US9522176B2 (en) * 2013-10-22 2016-12-20 Shire Human Genetic Therapies, Inc. MRNA therapy for phenylketonuria
CA2928040A1 (en) * 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Cns delivery of mrna and uses thereof
PE20161242A1 (es) 2013-10-22 2016-12-11 Massachusetts Inst Technology Formulaciones de lipidos para la administracion de arn mensajero
WO2015138357A2 (en) 2014-03-09 2015-09-17 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of otc deficency
JP6372118B2 (ja) * 2014-03-18 2018-08-15 東洋インキＳｃホールディングス株式会社 両性界面活性剤とその製造方法
ME03314B (me) 2014-03-24 2019-10-20 Translate Bio Inc Irnk terapija za liječenje očnih oboljenja
FI3981437T3 (fi) 2014-04-23 2025-01-10 Modernatx Inc Nukleiinihapporokotteita
DK3134506T3 (da) 2014-04-25 2019-10-14 Translate Bio Inc Fremgangsmåder til oprensning af messenger rna
WO2015184256A2 (en) 2014-05-30 2015-12-03 Shire Human Genetic Therapies, Inc. Biodegradable lipids for delivery of nucleic acids
CA2951707A1 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
UA121863C2 (uk) * 2014-06-24 2020-08-10 Транслейт Байо, Інк. Стереохімічно збагачені композиції для доставки нуклеїнових кислот
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
BR112016030852A2 (pt) 2014-07-02 2018-01-16 Shire Human Genetic Therapies encapsulação de rna mensageiro
CA2955250A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
US10736966B2 (en) 2014-08-12 2020-08-11 Massachusetts Institute Of Technology Brush-poly (glycoamidoamine)-lipids and uses thereof
AU2015357562B2 (en) 2014-12-05 2021-10-21 Translate Bio, Inc. Messenger RNA therapy for treatment of articular disease
AU2016233135B2 (en) 2015-03-19 2021-07-08 Translate Bio, Inc. mRNA therapy for pompe disease
WO2016187531A1 (en) * 2015-05-21 2016-11-24 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derivatives and uses thereof
CA2989400A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 for the treatment of leptomeningeal carcinomatosis
DK3310764T3 (da) * 2015-06-19 2023-07-17 Massachusetts Inst Technology Alkenylsubstituerede 2,5-piperazindioner og deres anvendelse i sammensætninger til overførsel af et middel til et individ eller en celle
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
BR112018008078A2 (pt) 2015-10-22 2018-11-13 Modernatx Inc vacina de vírus influenza de amplo espectro
TN2018000155A1 (en) 2015-10-22 2019-10-04 Modernatx Inc Herpes simplex virus vaccine
PE20181530A1 (es) 2015-10-22 2018-09-26 Modernatx Inc Vacuna de virus sincitial respiratorio
JP6925688B2 (ja) 2015-10-22 2021-08-25 モデルナティーエックス， インコーポレイテッド 水痘帯状疱疹ウイルス（ｖｚｖ）のための核酸ワクチン
CA3002922A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
WO2017070626A2 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Respiratory virus vaccines
EP4039699A1 (en) 2015-12-23 2022-08-10 ModernaTX, Inc. Methods of using ox40 ligand encoding polynucleotides
WO2017120612A1 (en) 2016-01-10 2017-07-13 Modernatx, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
WO2017177169A1 (en) 2016-04-08 2017-10-12 Rana Therapeutics, Inc. Multimeric coding nucleic acid and uses thereof
JP7088911B2 (ja) 2016-05-18 2022-06-21 モデルナティエックス インコーポレイテッド リラキシンをコードするポリヌクレオチド
JP2019525947A (ja) 2016-06-01 2019-09-12 エムスリー・バイオテクノロジー・インコーポレイテッドＭ３ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 化合物
JP2019522047A (ja) 2016-06-13 2019-08-08 トランスレイト バイオ， インコーポレイテッド オルニチントランスカルバミラーゼ欠損症治療のためのメッセンジャーｒｎａ療法
RU2762607C2 (ru) 2016-09-13 2021-12-21 Аллерган, Инк. Стабилизированные небелковые композиции клостридиального токсина
AU2017345766A1 (en) 2016-10-21 2019-05-16 Modernatx, Inc. Human cytomegalovirus vaccine
MA46762A (fr) 2016-11-10 2019-09-18 Translate Bio Inc Procédé amélioré de préparation de nanoparticules lipidiques chargées d'arnm
MA46761A (fr) 2016-11-10 2019-09-18 Translate Bio Inc Administration sous-cutanée d'arn messager
EP3808380A1 (en) 2016-12-08 2021-04-21 CureVac AG Rna for treatment or prophylaxis of a liver disease
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
US11253605B2 (en) 2017-02-27 2022-02-22 Translate Bio, Inc. Codon-optimized CFTR MRNA
EP3585892B8 (en) 2017-02-27 2022-07-13 Translate Bio, Inc. Methods for purification of messenger rna
EP3585891B1 (en) 2017-02-27 2021-10-27 Translate Bio, Inc. Methods for purification of messenger rna
US10961184B2 (en) 2017-03-07 2021-03-30 Translate Bio, Inc. Polyanionic delivery of nucleic acids
WO2018170270A1 (en) * 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
EP3607074A4 (en) 2017-04-05 2021-07-07 Modernatx, Inc. REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
CN116693411A (zh) * 2017-04-28 2023-09-05 爱康泰生治疗公司 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
MX2019013752A (es) 2017-05-16 2020-07-20 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
WO2018236849A1 (en) 2017-06-19 2018-12-27 Translate Bio, Inc. Messenger rna therapy for the treatment of friedreich's ataxia
WO2019036008A1 (en) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
JP7461872B2 (ja) 2017-08-17 2024-04-04 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036028A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
US10278957B2 (en) 2017-09-11 2019-05-07 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
EP3461487A1 (en) * 2017-09-29 2019-04-03 Nlife Therapeutics S.L. Compositions and methods for the delivery of mrna to hepatic cells
US20200237922A1 (en) * 2017-10-17 2020-07-30 Sarepta Therapeutics, Inc. Bicyclic peptide oligonucleotide conjugates
WO2019079386A1 (en) * 2017-10-17 2019-04-25 Sarepta Therapeutics, Inc. CELL PENETRATION PEPTIDES FOR ANTISENSE ADMINISTRATION
EP3706729A4 (en) * 2017-11-06 2021-12-01 Nitto Denko Corporation FUSOGENIC COMPOUNDS FOR THE ADMINISTRATION OF BIOLOGICALLY ACTIVE MOLECULES
CN118291456A (zh) 2017-12-01 2024-07-05 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN110944675B9 (zh) 2017-12-01 2024-08-09 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CA3083970A1 (en) 2017-12-01 2019-06-06 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
EP3719126B1 (en) 2017-12-01 2025-01-01 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
JP7727308B2 (ja) 2017-12-01 2025-08-21 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 二本鎖オリゴヌクレオチド、二本鎖オリゴヌクレオチドを含む組成物および複合体ならびに調製方法と使用
EP3727428A1 (en) 2017-12-20 2020-10-28 Translate Bio, Inc. Improved composition and methods for treatment of ornithine transcarbamylase deficiency
KR102128951B1 (ko) * 2017-12-21 2020-07-01 탑월드(주) 비즈왁스와 동식물성 오일을 함유하는 화장료 조성물
CA3087106A1 (en) 2017-12-29 2019-07-04 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
EP3746496A1 (en) 2018-02-02 2020-12-09 Translate Bio, Inc. Cationic polymers
CN108467475B (zh) * 2018-03-08 2020-02-14 山西大学 一种环状聚合物及其制备方法和应用
US12370261B2 (en) 2018-03-16 2025-07-29 Sarepta Therapeutics, Inc. Chimeric peptides for antisense delivery
JP7448488B2 (ja) 2018-05-15 2024-03-12 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの皮下送達
EP3794008A1 (en) 2018-05-16 2021-03-24 Translate Bio, Inc. Ribose cationic lipids
AU2019275068B2 (en) 2018-05-24 2024-09-26 Translate Bio, Inc. Thioester cationic lipids
CN112424214A (zh) 2018-05-30 2021-02-26 川斯勒佰尔公司 包含甾族部分的阳离子脂质
JP2021525725A (ja) 2018-05-30 2021-09-27 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａワクチンおよびその使用
CA3101478A1 (en) 2018-05-30 2019-12-05 Translate Bio, Inc. Vitamin cationic lipids
JP2021525743A (ja) 2018-05-30 2021-09-27 トランスレイト バイオ， インコーポレイテッド リン酸エステルカチオン性脂質
CN108727209A (zh) * 2018-06-20 2018-11-02 复旦大学 具有n，n-二烷基亮氨酸结构的化合物及其制备方法
EP3810177B1 (en) 2018-06-21 2024-12-04 Ra Pharmaceuticals, Inc. Cyclic polypeptides for pcsk9 inhibition
WO2019246386A1 (en) 2018-06-21 2019-12-26 Ra Pharmaceuticals Inc. Cyclic polypeptides for pcsk9 inhibition
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
EP3810178A4 (en) 2018-06-21 2022-05-04 Merck Sharp & Dohme Corp. CYCLIC POLYPEPTIDES TO INHIBIT PCSK9
WO2019246352A1 (en) 2018-06-21 2019-12-26 Merck Sharp & Dohme Corp. Pcsk9 antagonist bicyclo-compounds
US11530244B2 (en) 2018-06-21 2022-12-20 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
JP7422977B2 (ja) 2018-07-23 2024-01-29 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａ用乾燥粉末製剤
WO2020033791A1 (en) 2018-08-09 2020-02-13 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
CN111655849B (zh) 2018-08-21 2024-05-10 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
CN118421617A (zh) 2018-08-24 2024-08-02 川斯勒佰尔公司 用于纯化信使rna的方法
KR20210091120A (ko) 2018-08-29 2021-07-21 트랜슬레이트 바이오 인코포레이티드 Mrna-로딩된 지질 나노입자를 제조하는 개선된 공정
KR20210102870A (ko) 2018-08-30 2021-08-20 테나야 테라퓨틱스, 인코포레이티드 미오카르딘 및 ascl1을 사용한 심장 세포 재프로그래밍
US20230145188A1 (en) 2018-09-14 2023-05-11 Translate Bio, Inc. Composition and methods for treatment of methylmalonic acidemia
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
EP3852911B1 (en) 2018-09-21 2025-01-22 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
CA3112837A1 (en) 2018-10-19 2020-04-23 Translate Bio, Inc. Pumpless encapsulation of messenger rna
EP3876990A4 (en) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
KR20210089648A (ko) 2018-11-08 2021-07-16 트랜슬레이트 바이오 인코포레이티드 메신저 rna 정제를 위한 방법 및 조성물
EP3876914A2 (en) 2018-11-09 2021-09-15 Translate Bio, Inc. Messenger rna therapy for treatment of ocular diseases
US20220016029A1 (en) 2018-11-09 2022-01-20 Translate Bio, Inc. Multi-peg lipid compounds
US12280147B2 (en) 2018-11-09 2025-04-22 Translate Bio, Inc. PEG lipidoid compounds
US20230071228A1 (en) * 2018-11-09 2023-03-09 Translate Bio, Inc. 2,5-dioxopiperazine lipids with intercalated ester, thioester, disulfide and anhydride moieities
EP3880174A2 (en) 2018-11-12 2021-09-22 Translate Bio, Inc. Methods for inducing immune tolerance
US12257305B2 (en) 2018-11-21 2025-03-25 Translate Bio, Inc. Cationic lipid compounds
MX2021005969A (es) 2018-11-21 2021-09-14 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado.
CA3118034A1 (en) 2018-12-21 2020-06-25 Curevac Ag Rna for malaria vaccines
CA3125588A1 (en) 2019-01-07 2020-07-16 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
CA3125511A1 (en) 2019-02-08 2020-08-13 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
WO2020214946A1 (en) 2019-04-18 2020-10-22 Translate Bio, Inc. Cystine cationic lipids
EP3959195B1 (en) 2019-04-22 2023-11-08 Translate Bio, Inc. Thioester cationic lipids
WO2020227085A1 (en) 2019-05-03 2020-11-12 Translate Bio, Inc. Di-thioester cationic lipids
CA3140423A1 (en) 2019-05-14 2020-11-19 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
US20220226244A1 (en) 2019-05-31 2022-07-21 Translate Bio, Inc. Macrocyclic lipids
US20220313813A1 (en) 2019-06-18 2022-10-06 Curevac Ag Rotavirus mrna vaccine
WO2020257611A1 (en) 2019-06-21 2020-12-24 Translate Bio, Inc. Cationic lipids comprising an hydroxy moiety
AU2020297606A1 (en) 2019-06-21 2022-01-20 Translate Bio, Inc. Tricine and citric acid lipids
CN119454644A (zh) 2019-07-08 2025-02-18 川斯勒佰尔公司 改善的负载mrna的脂质纳米颗粒和其制备方法
EP3997226A1 (en) 2019-07-11 2022-05-18 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with micrornas and other factors
EP4003311A1 (en) 2019-07-23 2022-06-01 Translate Bio, Inc. Stable compositions of mrna-loaded lipid nanoparticles and processes of making
IL290078B2 (en) 2019-07-30 2025-09-01 Translate Bio Inc Treatment of cystic fibrosis by administering mRNA encoding CFTR in the form of a fine spray
AU2020328855A1 (en) 2019-08-14 2022-03-03 CureVac SE RNA combinations and compositions with decreased immunostimulatory properties
WO2021041770A1 (en) 2019-08-30 2021-03-04 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds
US20240197825A1 (en) 2019-09-20 2024-06-20 Translate Bio, Inc. mRNA Encoding Engineered CFTR
WO2021061815A1 (en) 2019-09-23 2021-04-01 Omega Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4α) GENE EXPRESSION
CA3147641A1 (en) 2019-09-23 2021-04-01 Omega Therapeutics, Inc. Compositions and methods for modulating apolipoprotein b (apob) gene expression
JP7650873B2 (ja) 2019-10-09 2025-03-25 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの組成物、方法および使用
WO2021081058A1 (en) 2019-10-21 2021-04-29 Translate Bio, Inc. Compositions, methods and uses of messenger rna
JP7306252B2 (ja) * 2019-12-13 2023-07-11 東洋インキＳｃホールディングス株式会社 紐状ミセル組成物および含水ゲル
CN114901360A (zh) 2019-12-20 2022-08-12 库瑞瓦格股份公司 用于递送核酸的新型脂质纳米颗粒
US12053551B2 (en) 2019-12-20 2024-08-06 Translate Bio, Inc. Process of preparing mRNA-loaded lipid nanoparticles
JP7752615B2 (ja) 2019-12-20 2025-10-10 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの直腸送達
CA3163161A1 (en) 2020-01-09 2021-07-15 Gregory Lawrence HAMILTON Nanomaterials
WO2021142245A1 (en) 2020-01-10 2021-07-15 Translate Bio, Inc. Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
JP2023513502A (ja) 2020-02-04 2023-03-31 キュアバック エスイー コロナウイルスワクチン
JP7744354B2 (ja) * 2020-02-25 2025-09-25 トランスレイト バイオ， インコーポレイテッド Ｍｒｎａ担持脂質ナノ粒子を調製する改善された方法
US20230097743A1 (en) * 2020-03-02 2023-03-30 Trustees Of Tufts College Imidazole-based synthetic lipidoids for in vivo mrna delivery into immune cells
BR112022017551A2 (pt) 2020-03-02 2022-11-16 Tenaya Therapeutics Inc Controle de vetor genético por micrornas expressos por cardiomiócito
CA3173528A1 (en) 2020-03-11 2021-09-16 Omega Therapeutics, Inc. Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
WO2021189355A1 (en) * 2020-03-26 2021-09-30 Chinese Institute For Brain Research, Beijing Amino acid mediated gene delivery and its uses
KR20230008801A (ko) 2020-05-07 2023-01-16 트랜슬레이트 바이오 인코포레이티드 Sars-cov-2 항원을 암호화하는 최적화된 뉴클레오티드 서열
US20230181619A1 (en) 2020-05-07 2023-06-15 Translate Bio, Inc. Improved compositions for cftr mrna therapy
US20230190954A1 (en) 2020-05-07 2023-06-22 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
WO2021231697A1 (en) 2020-05-14 2021-11-18 Translate Bio, Inc. Peg lipidoid compounds
CN115916158A (zh) 2020-05-15 2023-04-04 翻译生物公司 用于mRNA递送的脂质纳米颗粒配制品
AU2021275213A1 (en) 2020-05-20 2023-02-02 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
MX2022014653A (es) 2020-05-20 2023-02-16 Flagship Pioneering Innovations Vi Llc Composiciones de antigeno de coronavirus y sus usos.
CN111517974A (zh) * 2020-05-28 2020-08-11 浙江昂拓莱司生物技术有限公司 一种氨基酸n端烷基化衍生物及其制备方法和应用
AU2021281453A1 (en) 2020-05-29 2022-11-17 Flagship Pioneering Innovations Vi, Llc. Trem compositions and methods relating thereto
WO2021243290A1 (en) 2020-05-29 2021-12-02 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods relating thereto
WO2021239880A1 (en) 2020-05-29 2021-12-02 Curevac Ag Nucleic acid based combination vaccines
US20240307556A1 (en) 2020-07-02 2024-09-19 Maritime Therapeutics, Inc. Compositions and methods for reverse gene therapy
MX2023000614A (es) 2020-07-16 2023-02-13 Acuitas Therapeutics Inc Lipidos cationicos para usarse en nanoparticulas lipidicas.
EP4172194A1 (en) 2020-07-31 2023-05-03 CureVac SE Nucleic acid encoded antibody mixtures
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
EP4157344A2 (en) 2020-08-31 2023-04-05 CureVac SE Multivalent nucleic acid based coronavirus vaccines
EP4208196A1 (en) 2020-09-03 2023-07-12 Flagship Pioneering Innovations VI, LLC Immunogenic compositions and uses thereof
WO2022060871A1 (en) 2020-09-15 2022-03-24 Verve Therapeutics, Inc. Lipid formulations for gene editing
US20230372440A1 (en) 2020-10-06 2023-11-23 Translate Bio, Inc. Improved process and formulation of lipid nanoparticles
EP4225272A1 (en) 2020-10-12 2023-08-16 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
WO2022081548A1 (en) 2020-10-12 2022-04-21 Translate Bio, Inc. Improved process of preparing ice-based lipid nanoparticles
US11771652B2 (en) * 2020-11-06 2023-10-03 Sanofi Lipid nanoparticles for delivering mRNA vaccines
WO2022099194A1 (en) 2020-11-09 2022-05-12 Translate Bio, Inc. Improved compositions for delivery of codon-optimized mrna
AU2021386737A1 (en) 2020-11-25 2023-07-13 Translate Bio, Inc. Stable liquid lipid nanoparticle formulations
US11932705B2 (en) 2020-12-18 2024-03-19 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
WO2022135993A2 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
MX2023007630A (es) 2020-12-23 2023-08-25 Flagship Pioneering Innovations Vi Llc Composiciones de trem modificadas y usos de las mismas.
CN116981692A (zh) 2021-01-14 2023-10-31 翻译生物公司 递送mRNA编码的抗体的方法和组合物
JP2024505449A (ja) 2021-01-20 2024-02-06 ビーム セラピューティクス インク． 生分解性特徴を含むナノ材料
CN116761888A (zh) 2021-01-20 2023-09-15 比姆医疗股份有限公司 纳米材料
CN116782951A (zh) * 2021-01-20 2023-09-19 比姆医疗股份有限公司 用于纳米材料的可电离脂质
CA3170747A1 (en) 2021-01-27 2022-08-04 Moritz THRAN Method of reducing the immunostimulatory properties of in vitro transcribed rna
CN117157101A (zh) 2021-02-08 2023-12-01 德克萨斯大学系统董事会 不饱和的树枝状聚合物组合物、有关的制剂、及其使用方法
EP4314290A4 (en) 2021-03-23 2025-01-15 Recode Therapeutics, Inc. POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS AND METHODS OF USE THEREOF
US20250268994A1 (en) 2021-03-25 2025-08-28 Translate Bio, Inc. Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof
CA3212653A1 (en) 2021-03-26 2022-09-29 Glaxosmithkline Biologicals Sa Immunogenic compositions
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
WO2022207862A2 (en) 2021-03-31 2022-10-06 Curevac Ag Syringes containing pharmaceutical compositions comprising rna
US20250073351A1 (en) 2021-04-19 2025-03-06 Translate Bio, Inc. Improved compositions for delivery of mrna
WO2022233880A1 (en) 2021-05-03 2022-11-10 Curevac Ag Improved nucleic acid sequence for cell type specific expression
US20230043128A1 (en) 2021-06-18 2023-02-09 Sanofi Multivalent influenza vaccines
EP4362920A1 (en) 2021-07-01 2024-05-08 Translate Bio, Inc. Compositions for delivery of mrna
EP4367242A2 (en) 2021-07-07 2024-05-15 Omega Therapeutics, Inc. Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
US20240336945A1 (en) 2021-07-26 2024-10-10 Flagship Pioneering Innovations Vi, Llc Trem compositions and uses thereof
US20240342206A1 (en) 2021-07-30 2024-10-17 CureVac SE mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
CA3230031A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids
EP4395820A2 (en) 2021-09-03 2024-07-10 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
EP4271818B1 (en) 2021-09-17 2024-07-31 Flagship Pioneering Innovations VI, LLC Compositions and methods for producing circular polyribonucleotides
MX2024004253A (es) 2021-10-05 2024-06-28 Sanofi Sa Métodos para congelar y liofilizar nanopartículas lipídicas (lnp) y lnp obtenidas mediante los mismos.
WO2023059806A1 (en) 2021-10-06 2023-04-13 Massachusetts Institute Of Technology Lipid nanoparticles for drug delivery to microglia in the brain
CN118382705A (zh) 2021-10-18 2024-07-23 旗舰创业创新六公司 用于纯化多核糖核苷酸的组合物和方法
US20250295755A1 (en) 2021-10-22 2025-09-25 Sail Biomedicines, Inc. Mrna vaccine composition
US20250027108A1 (en) 2021-10-29 2025-01-23 CureVac SE Improved circular rna for expressing therapeutic proteins
IL312334A (en) 2021-11-05 2024-06-01 Sanofi Sa RNA vaccine for respiratory syncytial virus
EP4429713A1 (en) 2021-11-10 2024-09-18 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
CN118488834A (zh) 2021-11-23 2024-08-13 赛欧生物医药股份有限公司 细菌源性脂质组合物和其用途
MX2024006440A (es) 2021-11-24 2024-08-19 Flagship Pioneering Innovations Vi Llc Composiciones inmunogenicas y sus usos.
CN118401544A (zh) 2021-11-24 2024-07-26 旗舰创业创新六公司 水痘-带状疱疹病毒免疫原组合物及其用途
IL313004A (en) 2021-11-24 2024-07-01 Flagship Pioneering Innovations Vi Llc Coronavirus immunogen compositions and their uses
JP2024542635A (ja) 2021-11-30 2024-11-15 サノフィ パスツール インコーポレイテッド ヒトメタニューモウイルスワクチン
EP4448485A2 (en) 2021-12-16 2024-10-23 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
AR128002A1 (es) 2021-12-17 2024-03-20 Flagship Pioneering Innovations Vi Llc Métodos de enriquecimiento de rna circular en condiciones desnaturalizantes
WO2023111262A1 (en) 2021-12-17 2023-06-22 Sanofi Lyme disease rna vaccine
WO2023122080A1 (en) 2021-12-20 2023-06-29 Senda Biosciences, Inc. Compositions comprising mrna and lipid reconstructed plant messenger packs
US20250051386A1 (en) 2021-12-22 2025-02-13 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
CA3241026A1 (en) 2021-12-23 2023-06-29 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
WO2023141538A1 (en) * 2022-01-20 2023-07-27 Ohio State Innovation Foundation Compositions comprising lipid compounds and methods of making and use thereof
WO2023144193A1 (en) 2022-01-25 2023-08-03 CureVac SE Mrnas for treatment of hereditary tyrosinemia type i
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
EP4482962A1 (en) 2022-02-24 2025-01-01 IO Biotech ApS Nucleotide delivery of cancer therapy
EP4499607A1 (en) 2022-03-25 2025-02-05 Sail Biomedicines, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
CN119325466A (zh) * 2022-04-08 2025-01-17 尚威天成信使核糖核酸治疗公司 可电离脂质化合物和脂质纳米颗粒组合物
WO2023196634A2 (en) 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
CA3256624A1 (en) 2022-05-06 2023-11-09 Sanofi SIGNAL SEQUENCES FOR NUCLEIC ACID-BASED VACCINES
WO2023220083A1 (en) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use for treating proliferative disorders
WO2023220729A2 (en) 2022-05-13 2023-11-16 Flagship Pioneering Innovations Vii, Llc Double stranded dna compositions and related methods
US20250345407A1 (en) 2022-05-25 2025-11-13 CureVac SE Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
CN117460710B (zh) * 2022-06-02 2025-08-05 厦门赛诺邦格生物科技股份有限公司 一种氨基酸阳离子脂质
CN117460711B (zh) * 2022-06-02 2025-07-08 厦门赛诺邦格生物科技股份有限公司 一种含有不饱和键的氨基酸阳离子脂质
EP4544043A1 (en) 2022-06-22 2025-04-30 Flagship Pioneering Innovations VI, LLC Compositions of modified trems and uses thereof
KR20250028290A (ko) 2022-06-30 2025-02-28 사노피 선택적 il-23 수용체 길항제로서의 새로운 펩티드
CA3260437A1 (en) 2022-07-20 2024-01-25 Beam Therapeutics Inc NANOMATERIALS INCLUDING TRIOLS
WO2024030856A2 (en) 2022-08-01 2024-02-08 Flagship Pioneering Innovations Vii, Llc Immunomodulatory proteins and related methods
EP4565209A1 (en) 2022-08-04 2025-06-11 Sanofi Pasteur Inc. Quantitative assessment of rna encapsulation
EP4569112A1 (en) 2022-08-12 2025-06-18 Remix Therapeutics Inc. Methods and compositions for modulating splicing at alternative splice sites
WO2024044108A1 (en) 2022-08-22 2024-02-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccines against coronaviruses
JP2025530781A (ja) 2022-08-31 2025-09-17 セイル バイオメディシンズ インコーポレイテッド 新規のイオン化可能な脂質および脂質ナノ粒子ならびにそれらの使用方法
JP2025532686A (ja) 2022-09-26 2025-10-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザウイルスワクチン
EP4598946A1 (en) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
US12186389B2 (en) 2022-10-28 2025-01-07 Glaxosmithkline Biologicals Sa Nucleic acid base vaccine against emerging SARS-CoV-2 variants
EP4612296A1 (en) 2022-10-31 2025-09-10 Flagship Pioneering Innovations VI, LLC Compositions and methods for purifying polyribonucleotides
EP4612173A1 (en) 2022-11-04 2025-09-10 Sanofi Pasteur Inc. Respiratory syncytial virus rna vaccination
TW202434728A (zh) 2022-11-08 2024-09-01 美商旗艦先鋒創新有限責任公司 用於產生環狀多核糖核苷酸的組成物和方法
CN120359023A (zh) 2022-11-10 2025-07-22 赛欧生物医药股份有限公司 包含脂质纳米颗粒或脂质重构的天然信使包的rna组合物
EP4622630A1 (en) 2022-11-21 2025-10-01 Translate Bio, Inc. Compositions of dry powder formulations of messenger rna and methods of use thereof
EP4630057A1 (en) 2022-12-08 2025-10-15 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 用於將治療劑遞送至骨之組成物和方法
AU2023394992A1 (en) 2022-12-15 2025-07-31 Sanofi Pasteur Inc. Mrna encoding influenza virus-like particle
AR131438A1 (es) 2022-12-20 2025-03-19 Sanofi Sa VACUNA DE ARNm DE RINOVIRUS
WO2024151685A1 (en) 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant nucleic acid molecules and their use in wound healing
US20240238473A1 (en) 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant nucleic acid molecules and their use in wound healing
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
TW202438673A (zh) 2023-01-09 2024-10-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 疫苗及相關方法
KR20250153793A (ko) 2023-01-27 2025-10-27 세일 바이오메디슨스, 인크. 변형된 지질 조성물 및 이의 용도
EP4658239A1 (en) 2023-02-03 2025-12-10 GlaxoSmithKline Biologicals S.A. Rna formulation
WO2024167885A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
US20240293318A1 (en) 2023-02-13 2024-09-05 Flagship Pioneering Innovations Vii, Llc Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions
GB202302092D0 (en) 2023-02-14 2023-03-29 Glaxosmithkline Biologicals Sa Analytical method
WO2024173828A1 (en) 2023-02-17 2024-08-22 Flagship Pioneering Innovations Vii, Llc Dna compositions comprising modified uracil
US20240293582A1 (en) 2023-02-17 2024-09-05 Flagship Pioneering Innovations Vii, Llc Dna compositions comprising modified cytosine
WO2024177424A1 (ko) * 2023-02-24 2024-08-29 에스티팜 주식회사 신규 이온화 가능한 지질 및 이를 포함하는 지질나노입자
US12263213B2 (en) 2023-03-02 2025-04-01 Sanofi Pasteur Compositions for use in treatment of Chlamydia
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
WO2024192422A1 (en) 2023-03-15 2024-09-19 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
WO2024192420A1 (en) 2023-03-15 2024-09-19 Flagship Pioneering Innovations Vi, Llc Compositions comprising polyribonucleotides and uses thereof
AU2024252590A1 (en) 2023-04-12 2025-10-23 Flagship Pioneering Innovations Vi, Llc Trems for use in correction of missense mutations
WO2024216191A1 (en) 2023-04-12 2024-10-17 Flagship Pioneering Innovations Vi, Llc Modified trems, compositions, and related methods thereof
AU2024256347A1 (en) 2023-04-17 2025-11-27 Sanofi Pasteur Inc. Reconstitutable dry powder formulations and methods of use thereof
WO2024220752A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Rna therapeutic compositions
WO2024220712A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Vaccine compositions
WO2024220625A1 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
WO2024220746A2 (en) 2023-04-21 2024-10-24 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting fatty acid synthase and related methods
AU2024260120A1 (en) 2023-04-27 2025-11-06 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024223724A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
TW202500750A (zh) 2023-05-05 2025-01-01 法商賽諾菲公司 用於治療痤瘡的組成物
TW202508620A (zh) 2023-05-10 2025-03-01 尼可拉斯 克拉克 呼吸道mrna組合疫苗
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
WO2024243438A2 (en) 2023-05-23 2024-11-28 Omega Therapeutics, Inc. Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
WO2024246358A1 (en) 2023-06-01 2024-12-05 Sanofi Thermostable compositions comprising mrna lipid nanoparticles
WO2024258829A1 (en) 2023-06-12 2024-12-19 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
TW202506117A (zh) 2023-06-26 2025-02-16 英商維羅納製藥Ｐｌｃ公司 顆粒組成物
WO2025006684A1 (en) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
WO2025003760A1 (en) 2023-06-28 2025-01-02 Sanofi Sterol analogs in lipid nanoparticle formulations
WO2025010554A1 (en) * 2023-07-07 2025-01-16 Yoltech Therapeutics Co., Ltd. Lipid compounds for delivery of therapeutic agents and preparation method and its use thereof
WO2025011529A2 (en) 2023-07-07 2025-01-16 Shanghai Circode Biomed Co., Ltd. Circular rna vaccines for seasonal flu and methods of uses
WO2025017202A2 (en) 2023-07-19 2025-01-23 Sanofi Porphyromonas gingivalis antigenic constructs
TW202516001A (zh) 2023-07-25 2025-04-16 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 Ｃａｓ內切酶及相關方法
WO2025042786A1 (en) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
WO2025045142A1 (en) 2023-08-29 2025-03-06 Shanghai Circode Biomed Co., Ltd. Circular rna encoding vegf polypeptides, formulations, and methods of uses
WO2025049925A2 (en) * 2023-09-01 2025-03-06 Poseida Therapeutics, Inc. Lipidoid compounds and related compositions and uses
EP4520345A1 (en) 2023-09-06 2025-03-12 Myneo Nv Product
AR133753A1 (es) 2023-09-06 2025-10-29 Sanofi Sa Polipéptidos y ácidos nucleicos de hemaglutinina de la gripe b modificados y usos de los mismos
WO2025054236A2 (en) 2023-09-06 2025-03-13 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025051912A1 (en) 2023-09-08 2025-03-13 Sanofi New peptides as selective il-23 receptor inhibitors
WO2025051920A1 (en) 2023-09-08 2025-03-13 Sanofi New peptides as selective il-23 receptor inhibitors
WO2025064475A2 (en) 2023-09-18 2025-03-27 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof
WO2025072331A1 (en) 2023-09-26 2025-04-03 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025090023A1 (en) * 2023-10-24 2025-05-01 Agency For Science, Technology And Research A compound for preparing lipid nanoparticles encapsulating an agent, nanoparticle composition comprising said compound, and related methods thereof
WO2025096807A2 (en) 2023-10-31 2025-05-08 Flagship Pioneering Innovations Vii, Llc Novel therapeutic dna forms
WO2025106670A1 (en) 2023-11-14 2025-05-22 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof
WO2025106930A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof
WO2025106915A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
US20250161347A1 (en) 2023-11-22 2025-05-22 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease
WO2025117877A2 (en) 2023-12-01 2025-06-05 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
US12364773B2 (en) 2023-12-01 2025-07-22 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2025137646A1 (en) 2023-12-22 2025-06-26 Recode Therapeutics, Inc. Gene editing methods and compositions for treating cystic fibrosis
WO2025141521A1 (en) 2023-12-29 2025-07-03 Sanofi Lipids having dendritic moieties
WO2025160334A1 (en) 2024-01-26 2025-07-31 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025194019A1 (en) 2024-03-14 2025-09-18 Flagship Pioneering Innovations Vii, Llc Methods for treating liver fibrosis and non-alcoholic fatty liver disease
WO2025196065A1 (en) 2024-03-20 2025-09-25 Sanofi Novel homocysteine based lipids and their use for delivery of nucleic acids
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation
WO2025210592A1 (en) 2024-04-05 2025-10-09 Sanofi Pasteur Inc. Muscle cell lnp-mrna quality control assays
WO2025217275A2 (en) 2024-04-10 2025-10-16 Flagship Pioneering Innovations Vii, Llc Immune cell targeted compositions and related methods
WO2025240680A1 (en) 2024-05-16 2025-11-20 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025245188A2 (en) 2024-05-21 2025-11-27 Flagship Pioneering Innovations Vii, Llc Methods of treating liver steatosis and non-alcoholic fatty liver disease
WO2025245111A1 (en) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Immunoreceptor targeting proteins and related methods
CN118652301B (zh) * 2024-08-19 2024-12-13 仁景(苏州)生物科技有限公司 药物递送系统

Family Cites Families (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2844629A (en) 1956-04-25 1958-07-22 American Home Prod Fatty acid amides and derivatives thereof
NL269967A (es) * 1960-10-05
DE1155118B (de) 1961-12-30 1963-10-03 Basf Ag Verfahren zur Herstellung von am Stickstoffatom substituierten Sulfonamiden
DE1191629B (de) * 1962-03-16 1965-04-22 Basf Ag Fungizide Mittel
BE642774A (es) * 1963-04-02 1964-07-22
US3542581A (en) * 1968-11-05 1970-11-24 Eastman Kodak Co Method of de-aggregating oxonol dye-containing gelatin layers
JPS515430B1 (es) 1971-05-10 1976-02-19
GB1361627A (en) 1970-08-04 1974-07-30 Marumo H Detergent composition
US4258061A (en) * 1970-08-07 1981-03-24 Pfizer Inc. Interferon induction in animals by amines
JPS5120639B1 (es) * 1971-05-10 1976-06-26
US4022833A (en) 1973-02-14 1977-05-10 Sterling Drug Inc. N,N'-bridged-bis[2-alkyl-2-hydroxyethylamines]
JPS49127908A (es) 1973-04-20 1974-12-07
JPS5123537A (ja) 1974-04-26 1976-02-25 Adeka Argus Chemical Co Ltd Kasozaisoseibutsu
JPS5813576B2 (ja) 1974-12-27 1983-03-14 アデカ ア−ガスカガク カブシキガイシヤ 安定化された合成高分子組成物
DE2520814A1 (de) 1975-05-09 1976-11-18 Bayer Ag Lichtstabilisierung von polyurethanen
JPS5282910A (en) * 1975-12-30 1977-07-11 Kimio Kawakita Detergent composition
US4265745A (en) 1977-05-25 1981-05-05 Teijin Limited Permselective membrane
US4308085A (en) 1980-07-28 1981-12-29 Jenoptik Jena Gmbh Process for the preparation of high molecular thermoplastic epoxide-amine-polyadducts
JPS5774371A (en) * 1980-10-27 1982-05-10 Nippon Paint Co Ltd Improver for adhesion between coating film layers and paint composition containing the same
DE3143726C2 (de) * 1981-11-04 1987-02-05 Degussa Ag, 6000 Frankfurt Optisch aktive Prolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
CA1320724C (en) 1985-07-19 1993-07-27 Koichi Kanehira Terpene amino alcohols and medicinal uses thereof
DE3685861T2 (de) 1985-08-05 1992-12-17 Miyoshi Yushi Kk Verfahren fuer die abscheidung von metallen.
DE3616824A1 (de) 1986-05-17 1987-11-19 Schering Ag Verwendung von haertbaren kunstharzmischungen fuer oberflaechenbeschichtungen und druckfarben und verfahren zu ihrer herstellung
JPH07115545B2 (ja) * 1986-08-05 1995-12-13 株式会社リコー 可逆性感熱記録材料
US4720517A (en) 1986-11-24 1988-01-19 Ciba-Geigy Corporation Compositions stabilized with N-hydroxyiminodiacetic and dipropionic acids and esters thereof
US4873370A (en) 1987-03-03 1989-10-10 Pennzoil Products Company Alkylene diamines for use in friction and wear reducing compositions
US4782105A (en) * 1987-04-10 1988-11-01 Ciba-Geigy Corporation Long chain N,N,-dialkylhydroxylamines and stabilized compositions
JPH0832856B2 (ja) * 1987-05-15 1996-03-29 日本ペイント株式会社 塗料組成物
JPH07116064B2 (ja) * 1987-07-21 1995-12-13 三菱化学株式会社 分離剤
EP0436612A4 (en) * 1988-09-30 1992-05-20 Australian Commercial Research & Development Limited Amino acid transport proteins, amino acid analogues, assay apparatus, uses thereof for treatment and diagnosis of cancer
ZA899436B (en) * 1988-12-12 1990-08-29 Ciba Geigy Piperidine derivatives
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
JPH04225954A (ja) * 1990-05-02 1992-08-14 Yoshitomi Pharmaceut Ind Ltd アミド化合物、その医薬用途および新規１−置換ピロリジンメチルアミン類
US5693338A (en) * 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
JPH04364112A (ja) * 1991-06-11 1992-12-16 Mitsubishi Petrochem Co Ltd 水性液体洗浄剤組成物
JP2684276B2 (ja) 1991-11-27 1997-12-03 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
DE4218744C2 (de) 1992-06-04 1997-11-06 Schering Ag Verfahren zur Herstellung von N-ß-Hxdroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecan- und N-ß-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivaten und deren Metallkomplexe
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5380778A (en) 1992-09-30 1995-01-10 Minnesota Mining And Manufacturing Company Fluorochemical aminoalcohols
JPH06211978A (ja) 1992-10-28 1994-08-02 Takeda Chem Ind Ltd 新規ポリエーテルポリオール及びそれを用いる軟質ウレタンフォームの製造法
US6020317A (en) 1993-02-19 2000-02-01 Nippon Shinyaku Co. Ltd. Glycerol derivative, device and pharmaceutical composition
US5624976A (en) 1994-03-25 1997-04-29 Dentsply Gmbh Dental filling composition and method
FR2707289B1 (fr) * 1993-07-06 1995-08-11 Chemoxal Sa Procédé de préparation d'un composé hydroxylé d'amine secondaire ou tertiaire.
US5585391A (en) * 1993-10-08 1996-12-17 Fhj Scientific, Inc. Hydroxyl ions as unique therapeutic agents and compounds that modulate these ions, compositions employing these agents, therapeutic methods for using such agents and processes for preparing them
JPH09505593A (ja) 1993-11-24 1997-06-03 メガバイオス・コーポレイション ピペラジンの両親媒性誘導体
US5464924A (en) 1994-01-07 1995-11-07 The Dow Chemical Company Flexible poly(amino ethers) for barrier packaging
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US5679852A (en) * 1995-06-02 1997-10-21 Schering Aktiengesellschaft Process for the production of DTPA-monoamides of the central carboxylic acid and their use as pharmaceutical agents
JPH0913066A (ja) * 1995-06-26 1997-01-14 Kao Corp ディーゼルエンジン用潤滑油添加剤及び潤滑油組成物
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
JPH0995691A (ja) * 1995-09-28 1997-04-08 Sony Corp 潤滑剤およびこれを用いた磁気記録媒体
FR2741066B1 (fr) 1995-11-14 1997-12-12 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
US6344436B1 (en) * 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
NL1003008C2 (nl) * 1996-05-03 1997-11-06 Dsm Nv Met een heteroatoom-bevattende groep gesubstitueerde cyclopentadieen- verbinding.
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
JPH10197978A (ja) 1997-01-09 1998-07-31 Mitsubishi Paper Mills Ltd ハロゲン化銀写真感光材料
AU7173698A (en) * 1997-05-02 1998-11-27 Baylor College Of Medicine Lipophilic and/or lytic peptides for specific delivery of nucleic acids to ce lls
JPH115786A (ja) 1997-06-13 1999-01-12 Pola Chem Ind Inc 新規アミノヒドロキシプロピルピペラジン誘導体
JPH11241095A (ja) * 1997-08-04 1999-09-07 Ajinomoto Co Inc 頭髪化粧料組成物
JPH11106329A (ja) * 1997-08-04 1999-04-20 Ajinomoto Co Inc 化粧料組成物
JPH1180142A (ja) 1997-09-05 1999-03-26 Pola Chem Ind Inc ジフェニルアルキル化合物の製造法
AU730364B2 (en) * 1997-09-23 2001-03-08 Bristol-Myers Squibb Company Selective cPLA2 inhibitors
FR2774092B1 (fr) 1998-01-26 2000-02-18 Air Liquide Procede de preparation de polyazacycloalcanes greffes sur gel de silice et utilisation des composes greffes
DE19822602A1 (de) 1998-05-20 1999-11-25 Goldschmidt Ag Th Verfahren zur Herstellung von Polyaminosäureestern durch Veresterung von sauren Polyaminosäuren oder Umesterung von Polyaminosäureestern
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6696424B1 (en) 1999-05-28 2004-02-24 Vical Incorporated Cytofectin dimers and methods of use thereof
EP1808438B1 (en) 1999-06-29 2014-10-01 MannKind Corporation Purification and stabilization of peptide and proteins in pharmaceutical agents
DE19937721A1 (de) 1999-08-10 2001-02-15 Max Planck Gesellschaft Neue Diketopiperazine
IL150484A0 (en) 1999-12-30 2002-12-01 Novartis Ag Novel colloid synthetic vectors for gene therapy
IL138474A0 (en) 2000-09-14 2001-10-31 Epox Ltd Highly branched water-soluble polyamine oligomers, process for their preparation and applications thereof
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7427394B2 (en) 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US6656977B2 (en) 2001-07-20 2003-12-02 Air Products And Chemical, Inc. Alkyl glycidyl ether-capped polyamine foam control agents
US7101995B2 (en) 2001-08-27 2006-09-05 Mirus Bio Corporation Compositions and processes using siRNA, amphipathic compounds and polycations
AU2002326948A1 (en) * 2001-09-18 2003-04-01 Bristol-Myers Squibb Company Piperizinones as modulators of chemokine receptor activity
AU2002347035B2 (en) 2001-09-28 2008-04-03 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V Micro-RNA molecules
DE10207178A1 (de) 2002-02-19 2003-09-04 Novosom Ag Komponenten für die Herstellung amphoterer Liposomen
US20030215395A1 (en) 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US7601367B2 (en) 2002-05-28 2009-10-13 Mirus Bio Llc Compositions and processes using siRNA, amphipathic compounds and polycations
AU2003301852A1 (en) 2002-11-04 2004-06-07 Ge Bayer Silicones Gmbh And Co. Kg Linear polyamino and/or polyammonium polysiloxane copolymers i
AU2003281978A1 (en) * 2002-11-22 2004-06-18 Boehringer Ingelheim International Gmbh 2,5-diketopiperazines for the treatment of obesity
US6998508B2 (en) 2003-03-10 2006-02-14 Air Products And Chemicals, Inc. Tertiary alkanolamines containing surface active alkyl groups
US6781537B1 (en) 2003-06-10 2004-08-24 Nortel Networks Limited High speed digital to analog converter
US7507859B2 (en) 2003-06-16 2009-03-24 Fifth Base Llc Functional synthetic molecules and macromolecules for gene delivery
US20050123596A1 (en) 2003-09-23 2005-06-09 Kohane Daniel S. pH-triggered microparticles
CN1946772B (zh) 2004-04-20 2013-01-02 德瑞迪克纳米科技公司 具有增强的扩增性和内部官能度的树枝状聚合物
JP4796062B2 (ja) 2004-06-07 2011-10-19 プロチバ バイオセラピューティクス インコーポレイティッド 脂質封入干渉ｒｎａ
US20060035893A1 (en) * 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
EP1791542B1 (en) 2004-08-23 2015-05-20 Mannkind Corporation Diketopiperazine salts for drug delivery
DE102004043342A1 (de) 2004-09-08 2006-03-09 Bayer Materialscience Ag Blockierte Polyurethan-Prepolymere als Klebstoffe
GB0502482D0 (en) 2005-02-07 2005-03-16 Glaxo Group Ltd Novel compounds
CA2599328C (en) * 2005-02-23 2012-04-17 Shionogi & Co., Ltd. Quinazoline derivative having tyrosine kinase inhibitory activity
EP1869106B1 (en) 2005-03-28 2014-06-25 Dendritic Nanotechnologies, Inc. Janus dendrimers and dendrons
WO2006138380A2 (en) 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
KR101643478B1 (ko) 2005-09-14 2016-07-27 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
US20090221684A1 (en) 2005-12-22 2009-09-03 Trustees Of Boston University Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof
CN100569877C (zh) 2005-12-30 2009-12-16 财团法人工业技术研究院 含多uv交联反应基的分枝状结构化合物及其应用
MX2008010721A (es) 2006-02-22 2008-09-01 Mannkind Corp Un metodo para mejorar las propiedades farmaceuticas de microparticulas que contienen dicetopiperazina y un agente activo.
US8628750B2 (en) * 2006-02-27 2014-01-14 Technische Universitat Munchen Cancer imaging and treatment
US20070275923A1 (en) 2006-05-25 2007-11-29 Nastech Pharmaceutical Company Inc. CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
CA2654302A1 (en) 2006-06-05 2007-12-13 Massachusetts Institute Of Technology Crosslinked, degradable polymers and uses thereof
ES2293834B1 (es) * 2006-07-20 2009-02-16 Consejo Superior Investig. Cientificas Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas.
US8071082B2 (en) 2006-07-21 2011-12-06 Massachusetts Institute Of Technology End-modified poly(beta-amino esters) and uses thereof
CN101535238A (zh) 2006-11-01 2009-09-16 普罗诺瓦生物医药挪威公司 作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质
WO2008092091A2 (en) 2007-01-26 2008-07-31 Jenrin Discovery Mao inhibiting n-benzyl-n-propargyl-amines useful for treating obesity
EP2139461A2 (en) 2007-03-20 2010-01-06 Recepticon Aps Amino derivatives to prevent nephrotoxicity and cancer
JP5186126B2 (ja) 2007-03-29 2013-04-17 公益財団法人地球環境産業技術研究機構 新規トリアジン誘導体ならびにその製法およびそのガス分離膜としての用途
US8678686B2 (en) 2007-05-01 2014-03-25 Pgr-Solutions Multi-chain lipophilic polyamines
WO2008139855A1 (ja) * 2007-05-08 2008-11-20 Osaka Prefecture University Public Corporation 低級アシル基含有ポリアミドアミンデンドロン脂質
ES2364686T3 (es) 2007-08-27 2011-09-12 Theravance, Inc. Compuestos de alquil-8-azabiciclo[3.2.1]octano disustituidos como antagonistas del receptor opioide mu.
GB0716897D0 (en) * 2007-08-30 2007-10-10 Univ Muenchen Tech Cancer imaging and treatment
JP2009087966A (ja) 2007-09-27 2009-04-23 Fujifilm Corp 金属用研磨液及びそれを用いた研磨方法
EP2197495A2 (en) * 2007-10-02 2010-06-23 MDRNA, Inc. Lipopeptides for delivery of nucleic acids
WO2009086547A1 (en) 2008-01-03 2009-07-09 Cedars-Sinai Medical Center Antioxidant nanosphere comprising [1,2]-dithiolane moieties
ES2391600T3 (es) 2008-02-13 2012-11-28 Bristol-Myers Squibb Company Imidazoli bifenil imidazoles como inhibidores del virus de la hepatitis C
DE102008013500A1 (de) * 2008-03-10 2009-09-17 Evonik Degussa Gmbh Neue chirale Selektoren und stationäre Phasen zur Trennung von Enantiomerengemischen
WO2010042877A1 (en) 2008-10-09 2010-04-15 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
KR20110071017A (ko) 2008-10-16 2011-06-27 마리나 바이오테크, 인크. 유전자 침묵 치료제의 리포좀에 의한 효율적인 전달을 위한 프로세스 및 조성물
WO2010062322A2 (en) 2008-10-27 2010-06-03 Massachusetts Institute Of Technology Modulation of the immune response
MX353900B (es) 2008-11-07 2018-02-01 Massachusetts Inst Technology Lipidoides de aminoalcohol y usos de los mismos.
US8518994B2 (en) * 2008-12-26 2013-08-27 Nof Corporation Arginine derivative and cosmetic containing the same
WO2010078373A1 (en) * 2008-12-29 2010-07-08 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8314106B2 (en) * 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
WO2010096291A1 (en) * 2009-02-18 2010-08-26 The Lubrizol Corporation Compounds and a method of lubricating an internal combustion engine
US20100222489A1 (en) 2009-02-27 2010-09-02 Jiang Dayue D Copolymer composition, membrane article, and methods thereof
EP2415124B1 (en) * 2009-04-02 2017-02-15 The Siemon Company Telecommunications patch panel
KR20240015723A (ko) 2009-05-05 2024-02-05 알닐람 파마슈티칼스 인코포레이티드 지질 조성물
US20120196923A1 (en) 2009-05-15 2012-08-02 Kaushal Rege Polymers for delivering a substance into a cell
SG176738A1 (en) * 2009-06-12 2012-01-30 Mannkind Corp Diketopiperazine microparticles with defined specific surface areas
MX2012001339A (es) * 2009-07-30 2012-03-07 Salvat Lab Sa Compuestos inhibidores de apaf-1.
LT2506857T (lt) 2009-12-01 2018-07-10 Translate Bio, Inc. Mrnr tiekimas baltymų ir fermentų papildymui žmogaus genetinių ligų atvejais
GB0921871D0 (en) * 2009-12-15 2010-01-27 Univ Leuven Kath Novel antifungal compounds
US20110257431A1 (en) * 2010-03-18 2011-10-20 Basf Se Process for producing side product-free aminocarboxylates
CN101863544B (zh) 2010-06-29 2011-09-28 湖南科技大学 一种氰尿酸基重金属螯合絮凝剂及其制备方法
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
CN103261201B (zh) 2010-12-20 2015-04-22 格兰马克药品股份有限公司 作为trpa1拮抗剂的2-氨基-4-芳基噻唑化合物
CA2831392C (en) 2011-03-28 2020-04-28 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
WO2012133737A1 (ja) 2011-03-31 2012-10-04 公益財団法人地球環境産業技術研究機構 架橋性アミン化合物、該化合物を用いた高分子膜及びその製造方法
EP2532649B1 (en) 2011-06-07 2015-04-08 Incella GmbH Amino lipids, their synthesis and uses thereof
PL3586861T3 (pl) 2011-06-08 2022-05-23 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
ES2795110T3 (es) 2011-06-08 2020-11-20 Translate Bio Inc Lípidos escindibles
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
CL2014000988A1 (es) 2011-10-20 2014-11-03 Oryzon Genomics Sa Compuestos derivados de (aril o heteroaril) ciclopropilamida, inhibidores de lsd1; procedimiento para prepararlos; composicion farmaceutica que los comprende; y metodo para tratar o prevenir cancer, una enfermedad neurologica, una infeccion viral y la reactivacion viral despues de la latencia.
JP6151707B2 (ja) 2011-10-27 2017-06-21 マサチューセッツ インスティテュート オブ テクノロジー 薬物内包微小球の形成が可能なｎ−末端で官能基化されたアミノ酸誘導体
CA2884870C (en) 2012-08-13 2022-03-29 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
JP5991937B2 (ja) 2013-03-06 2016-09-14 Ｊｘエネルギー株式会社 摩擦調整剤および潤滑油組成物
SMT202100430T1 (it) 2013-03-14 2021-09-14 Translate Bio Inc Metodi e composizioni per il rilascio di anticorpi codificati da mrna
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
WO2014210356A1 (en) 2013-06-26 2014-12-31 Massachusetts Institute Of Technology Multi-tailed lipids and uses thereof
KR101355583B1 (ko) 2013-10-04 2014-01-24 한국지질자원연구원 간이 유용광물 분리 장치 및 이를 이용한 유용광물 분리 방법
CA2928040A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Cns delivery of mrna and uses thereof
PE20161242A1 (es) 2013-10-22 2016-12-11 Massachusetts Inst Technology Formulaciones de lipidos para la administracion de arn mensajero
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
DK3310764T3 (da) 2015-06-19 2023-07-17 Massachusetts Inst Technology Alkenylsubstituerede 2,5-piperazindioner og deres anvendelse i sammensætninger til overførsel af et middel til et individ eller en celle

Also Published As

Publication number Publication date
IL259414A (en) 2018-07-31
NZ747501A (en) 2020-05-29
US20200330501A1 (en) 2020-10-22
JP2019182867A (ja) 2019-10-24
NZ719941A (en) 2017-11-24
JP2017222642A (ja) 2017-12-21
AU2017265103A1 (en) 2017-12-14
AU2021257964A1 (en) 2021-11-25
KR102451116B1 (ko) 2022-10-06
SG11201401885TA (en) 2014-09-26
KR20200037431A (ko) 2020-04-08
KR20150000461A (ko) 2015-01-02
EA201490847A1 (ru) 2014-12-30
JP2021181463A (ja) 2021-11-25
UA119028C2 (uk) 2019-04-25
US10682374B2 (en) 2020-06-16
CN104136419B (zh) 2017-11-03
JP6151707B2 (ja) 2017-06-21
MX363734B (es) 2019-03-29
CA3119789A1 (en) 2013-05-02
EP4074694A1 (en) 2022-10-19
KR20220139428A (ko) 2022-10-14
JP7527650B2 (ja) 2024-08-05
IL250740A0 (en) 2017-04-30
MX2018008479A (es) 2021-06-15
AU2020201387A1 (en) 2020-03-12
CN107522664A (zh) 2017-12-29
AU2017265103B2 (en) 2019-11-28
KR102596685B1 (ko) 2023-11-01
MX2014005072A (es) 2014-07-28
US20230124955A1 (en) 2023-04-20
AU2021257964B2 (en) 2023-11-16
NZ733610A (en) 2019-11-29
US20180036333A9 (en) 2018-02-08
EA201891809A1 (ru) 2019-05-31
IL268756A (en) 2019-10-31
IL250740B (en) 2018-06-28
JP2023166457A (ja) 2023-11-21
ES2912739T3 (es) 2022-05-27
HK1201525A1 (en) 2015-09-04
IL232158A (en) 2017-02-28
CN113149869A (zh) 2021-07-23
US20190076462A1 (en) 2019-03-14
JP6973805B2 (ja) 2021-12-01
WO2013063468A1 (en) 2013-05-02
ZA201802716B (en) 2020-08-26
US11458158B2 (en) 2022-10-04
US20130158021A1 (en) 2013-06-20
BR112014010050A2 (pt) 2020-06-30
US9512073B2 (en) 2016-12-06
EP2771319B1 (en) 2022-03-02
NZ624223A (en) 2016-06-24
AU2012328570B2 (en) 2017-08-31
CN104136419A (zh) 2014-11-05
IL259414B (en) 2019-09-26
IL232158A0 (en) 2014-05-28
CA2853522C (en) 2021-07-13
CL2014001070A1 (es) 2014-11-21
AU2020201387B2 (en) 2021-07-29
CN107522664B (zh) 2021-03-16
BR112014010050A8 (pt) 2017-06-20
KR102272498B1 (ko) 2021-07-06
WO2013063468A8 (en) 2014-03-06
US20170165290A1 (en) 2017-06-15
PE20150041A1 (es) 2015-01-28
EA032088B1 (ru) 2019-04-30
CA2853522A1 (en) 2013-05-02
KR20210082570A (ko) 2021-07-05
IL268756B (en) 2020-08-31
EP2771319A1 (en) 2014-09-03
US10086013B2 (en) 2018-10-02
JP2014534220A (ja) 2014-12-18
AU2012328570A1 (en) 2014-05-22
JP6522690B2 (ja) 2019-05-29

Similar Documents

Publication Publication Date Title
PE20181541A1 (es) Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
ECSP23096498A (es) Restos de administración terapéutica novedosos y usos de estos
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
AR082995A1 (es) Profarmacos que comprenden un conjugado de conector de exendina
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
CO6491083A2 (es) Profarmacos que comprenden un conugado de insulina-conector
CL2008002787A1 (es) Compuestos derivados de piperidina, que presentan actividad moduladora sobre la actividad del receptor gpr 119; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades tales como diabetes tipo 1 y 2, hiperllpidemia, enfermedad coronaria, obesidad y disfuncion erectil.
CO6680667A2 (es) Derivados ester de ácido borónico cíclico y sus usos terapéuticos
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
UY35146A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
BRPI0910388A2 (pt) agentes terapêutico antivirais.
MX2013003635A (es) Compuestos de n-heteroarilo.
JP2015518818A5 (es)
UY33797A (es) Composiciones farmacéuticas para el tratamiento del vhc
CL2011001082A1 (es) Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2.
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
ECSP11011456A (es) Inhibidores de la replicación viral novedosos
GB2511685A (en) Muscarinic m1 receptor agonists
EA201590697A1 (ru) Производные кетамина
ECSP10010428A (es) Derivados de indazol
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
EA201590600A1 (ru) Дигидропирролидинопиримидины в качестве ингибиторов киназы